DOI: https://doi.org/10.24959/cphj.20.1520

The antidiabetic activity of the new composition “Thigliben” on the experimental dexamethasone diabetes mellitus model in rats

N. A. Tsubanova, O. H. Berdnyk

Abstract


Being a metabolic disease with long-term hyperglycemia, diabetes mellitus significantly increases the risk of microvascular and macrovascular diseases and organ pathologies, respectively. The creation of the new composition “Thigliben”, which allows not only qualitatively controlling diabetic hyperglycemia, but also providing a preventive and/or therapeutic effect on the development of diabetic polyneuropathy was pathogenetically reasonable.

Aim. To study the antidiabetic activity of “Thigliben” on the experimental dexamethasone diabetes mellitus in rats.

Materials and methods. The pharmacological study of the antidiabetic activity of the new composition “Thigliben” in the dose of 4 mg/kg was performed. The experimental studies were conducted on a standard model of the experimental dexamethasone type 2 diabetes mellitus in rats. Glibenclamide in the dose of 0.6 mg/kg (corresponds to an average human daily dose of 10 mg) was selected as the reference drug.

Results. It was found that by its effects on the carbohydrate and lipid metabolism the new composition “Thigliben” was similar to the reference drug glibenclamide administered in a higher dose. By the antioxidant activity this composition exceeded the effect of the reference drug, provided that normalization of the TBA-RS level in the liver homogenate was significant. The new composition “Thigliben” normalized all the parameters of the cerebral energy metabolism studied relative to the control pathology group and its efficiency was significantly higher than that of the reference drug glibenclamide. The new composition “Thigliben” increased the content of ATP by 109 % compared to the control pathology group, in contrast to 68 % on the background of glibenclamide; restored the activity of citrate synthase by 65 %, succinate dehydrogenase by 134 %, and pyruvate dehydrogenase by 61 % relative to the control pathology group. For glibenclamide the change in these indicators was 28 %, 50 %, and 22 %, respectively. The results obtained suggest that the metabolic effect of “Thigliben” composition is significantly more effective than that of the reference drug glibenclamide.

Conclusions. The new composition “Thigliben” is a promising antidiabetic drug with a pronounced hypolipidemic, antioxidant effect and the ability to restore energy deficiency; it is its significant advantage over the standard treatment regimens, including the average therapeutic doses of glibenclamide.


Keywords


diabetes mellitus type 2; experimental pharmacology; complex hypoglycemic drugs; glibenclamide

Full Text:

PDF

References


Meng, F., Sun, Y., Heng, B. H., & Leow, M. K. S. (2020). Analysis via Markov decision process to evaluate glycemic control strategies of a large retrospective cohort with type 2 diabetes: the ameliorate study. Acta Diabetologica. https://doi.org/10.1007/s00592-020-01492-x

Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., … Zimmerman, R. S. (2010). The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective analysis. Diabetes Care, 33(6), 1224–1229. https://doi.org/10.2337/dc10-0017

Achila, O. O., Ghebretinsae, M., Kidane, A., Simon, M., Makonen, S., & Rezene, Y. (2020). Factors Associated with Poor Glycemic and Lipid Levels in Ambulatory Diabetes Mellitus Type 2 Patients in Asmara, Eritrea: A Cross-Sectional Study. Journal of Diabetes Research, 2020, 1–12. https://doi.org/10.1155/2020/5901569

Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., … Holman, R. R. (2008). Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care, 31(5), 845–851. https://doi.org/10.2337/dc07-2270

Nasr, P., Fredrikson, M., Ekstedt, M., & Kechagias, S. (2020). The Amount of Liver Fat Predicts Mortality and Development of Type 2 Diabetes in Non‐alcoholic Fatty Liver Disease. Liver International. https://doi.org/10.1111/liv.14414

6. Pat. 134591 Ukraine. № u 201812544. (2019). Farmatsevtychna kompozytsiya dlya likuvannya tsukrovoho diabetu 2 typu.

Stefanov, O. V. (Eds.) (2001). Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsena.

Hrytsiuk, M. I., Boichuk, T. M., Petryshev, O. I. (2014). Svit medytsyny ta biolohii, 2(44), 199-203.

Rebrova, O. Yu. (2006). Statystycheskyi analyz medytsynskykh dannykh. Prymenenye paketa prykladnykh prohramm STATISTICA.Moscow: MedyaSfera, 312.

Buren, J., Ereksson, J. (1999). Dexamethasone decreases GLUT 1 and GLUT 4 content in primary cultured rat adipocytes. Diabetol, 42(1), 170-175.

Konrad, D., Somwar, R., Sweeney, G., Yaworsky, K., Hayashi, M., Ramlal, T., & Klip, A. (2001). The Antihyperglycemic Drug α-Lipoic Acid Stimulates Glucose Uptake via Both GLUT4 Translocation and GLUT4 Activation. Diabetes, 50(6), 1464–1471. https://doi.org/10.2337/diabetes.50.6.1464

Mohamed, A. K., Bierhaus, A., Schiekofer, S., Tritschler, H., Ziegler, R., & Nawroth, P. P. (1999). The role of oxidative stress and NF-κB activation in late diabetic complications. BioFactors, 10(2-3), 157–167. https://doi.org/10.1002/biof.5520100211


GOST Style Citations


1. Analysis via Markov decision process to evaluate glycemic control strategies of a large retrospective cohort with type 2 diabetes : the ameliorate study / F. Meng, Y. Sun, B. H. Heng, M. K. Leow // Acta Diabetol. – 2020. https://doi.org/10.1007/s00592-020-01492-x 

 

2. The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy. A retrospective analysis / K. M. Pantalone, M. W. Kattan, C. Yu et al. // Diabetes Care. – 2010. – № 33. – Р. 1224–1229. https://doi.org/10.2337/dc10-0017 

 

3. Factors Associated with Poor Glycemic and Lipid Levels in Ambulatory Diabetes Mellitus Type 2 Patients in Asmara, Eritrea: A Cross-Sectional Study / O. O. Achila, M. Ghebretinsae, A. Kidane et al. // Diabetes Res. – 2020. – Vol. 2020. https://doi.org/10.1155/2020/5901569 

 

4. A Diabetes Outcome Progression Trial [ADOPT] Study Group. Rosiglitazone-associated fractures in type 2 diabetes:an analysis from A Diabetes Outcome Progression Trial (ADOPT) / S. E. Kahn, B. Zinman, J. M. Lachin et al. // Diabetes Care. – 2008. – № 31. – P. 845-851. https://doi.org/10.2337/dc07-2270 

 

5. The Amount of Liver Fat Predicts Mortality and Development of Type 2 Diabetes in Non-alcoholic Fatty Liver Disease / P. Nasr, M. Fredrikson, M. Ekstedt, S. Kechagias // Liver Int. – 2020. https://doi.org/10.1111/liv.14414 

 

6. Фармацевтична композиція для лікування цукрового діабету 2 типу : пат. 134591 Україна. № u 201812544 ; заявл. 17.12.18 ; опубл. 27.05.19, Бюл. № 10.

 

7. Доклінічні дослідження лікарських засобів: метод. рек. / за ред. О. В. Стефанова. – К. : Авіцена, 2001. – С. 396-404.

 

8. Грицюк, М. І. Порівняльна характеристика експериментальних моделей цукрового діабету / М. І. Грицюк, Т. М. Бойчук, О. І. Петришев // Світ медицини та біол. – 2014. – № 2 (44). – С. 199-203.

 

9. Реброва, О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA / О. Ю. Реброва. – М. : МедиаСфера, 2006. – 312 с.

 

10. Buren, J. Dexamethasone decreases GLUT 1 and GLUT 4 content in primary cultured rat adipocytes / J. Buren, J. Ereksson // Diabetol. – 1999. – Vol. 42, № 1 – P. 170-175.

 

11. The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: potential role of p38 mitogen-activated protein kinase in GLUT4 activation / D. Konrad, R. Somwar, G. Sweeney et al. // Diabetes. – 2001. – Vol. 50. – P. 1464-1471. https://doi.org/10.2337/diabetes.50.6.1464 

 

12. The role of oxidative stress and NF-kappa B activation in late diabetic complications / A. K. Mohamed, A. Bierhaus, S. Schiekofer et al. // Biofactirs. – 1999. – Vol. 10, № 2-3. – P. 157-167. https://doi.org/10.1002/biof.5520100211 





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Clin. pharm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)